Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | C1R | P00736 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879921 | 0.82 | TAAR1 (0.34) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7461135 | 0.82 | TDP1 (0.38) | CYP2D6MEN1LMNATHRBBLM | |
| SCHEMBL7590927 | 0.77 | TAAR1 (0.54) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8344323 | 0.76 | TAAR1 (0.46) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28803517 | 0.76 | TAAR1 (0.46) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL249728 | 0.76 | GABRA1 (0.47) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28879912 | 0.76 | TAAR1 (0.46) | TAAR1IDO1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2043471 | 0.74 | — | — | |
| SCHEMBL28879923 | 0.73 | — | — | |
| SCHEMBL6446917 | 0.73 | GABRA1 (0.42) | CYP2D6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| CN-107428646-B | Compounds, resins, and methods for their purification, and uses thereof | 三菱瓦斯化学株式会社 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| CN-107428646-A | Compound, resin and their purification process, lower floor's film formation material of photoetching, lower membrane formation with composition and lower membrane and, corrosion-resisting pattern forming method and circuit pattern forming method | 三菱瓦斯化学株式会社 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017075341-A1 | FUSED IMIDAZOLE DERIVATIVES AS IDO/TDO INHIBITORS | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2015031824-A9 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015031824-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2697227-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012164085-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012142237-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICKS CORPORATION (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| EP-1799627-B1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | SALTIGO GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| EP-2097385-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | Merck & Co., Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008051532-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1799627-A1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | Ludwig-Maximilians-Universität München (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006040131-A1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | LUDWIG-MAXIMILIANS- UNIVERSITÄT MÜNCHEN (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SLC39A14, MAL2, AHR | TAAR1 1175/4885IDO1 94/4885CYP1A2 81/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | TAAR1 2937/4885IDO1 4238/4885CYP1A2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.